NATIONWIDE — The EpiPen will no longer be covered by a top health insurer.
Cigna will only be covering the generic version launched last month by the EpiPen manufacturer Mylan.
Mylan has been criticized by many for hiking the price more than 400 percent since 2009. A two-pack of pens costs more than $600. A two-pack of the generic EpiPen carries a list price of $300.
In response, CVS Health announced Thursday that it would sell a generic version of the EpiPen competitor.
The nation’s largest drugstore chain said it would sell the generic version of Impax Laboratories’ Adrenaclick treatment for $109.99 per two-pack before potential discounts, about one-third of Mylan’s initial list price.
The new price applies to both insured patients and those who pay cash without coverage.
Trump criticized drugmakers for hikes in drug prices. "They're getting away with murder," he said Wednesday of drug companies, whose stocks plunged afterward.
CVS's move comes amid scrutiny over the role of pharmacy benefit managers, like the CVS Caremark unit, in contributing to EpiPen increases.
The National Community Pharmacists Association recently called for a Congressional hearing on how pharmacy benefit managers have contributed to the "absurdly high" price.
RELATED: